For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

31st Jan 13

Pharmaxis Announces US$40 million Financing Agreement with NovaQuest

Pharmaceutical company Pharmaxis Ltd (ASX: PXS) is pleased to announce the signing of a Financing Agreement with NovaQuest Pharma Opportunities Fund III, LP (NovaQuest) under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for cystic fibrosis in the EU and US. 


Read full media release - pdf
31st Jan 13

Pharmaxis Receives Negative Recommendation from PADAC

Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has received a negative recommendation from a Committee advising the US Food and Drug Administration (FDA) on the use of Bronchitol® for cystic fibrosis patients in the United States.


Read full media release - pdf
22nd Jan 13

Conference Call Details

Pharmaxis Ltd (PXS) will release its December 2012 Quarterly Report to Shareholders on the afternoon of Wednesday 23rd January 2013.  Pharmaxis CEO, Dr Alan Robertson, will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday 24th January 2013 at 8.30am (Sydney time).

Online access:

Telephone access (toll free):

  • Australia: 1800 838 758 or 1800 131 617
  • USA/Canada:  1855 237 2970
  • UK: 0800 051 4282
  • NZ: 0800 447 258

Telephone access (metered): +61 2 9009 0730